Tailoring chemotherapy in advanced colorectal cancer

Current Opinion in Pharmacology

Volumn 3, Issue 4, 2003, Pages 378-385

  Park, David J ^a   Stoehlmacher, Jan ^a   Lenz, Heinz Josef ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; CAPECITABINE; CISPLATIN; CYTOCHROME P450 3A4; CYTOTOXIC AGENT; DEOXYURIDINE TRIPHOSPHATE PYROPHOSPHATASE; DIHYDROPYRIMIDINE DEHYDROGENASE; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; HELICASE; IRINOTECAN; MESSENGER RNA; OXALIPLATIN; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; PLATINUM DERIVATIVE; THYMIDYLATE SYNTHASE; TRANSCRIPTION FACTOR;

ADVANCED CANCER; BLOOD TOXICITY; BONE MARROW SUPPRESSION; COLORECTAL CANCER; DIARRHEA; DNA REPAIR; DRUG DEGRADATION; DRUG DETOXIFICATION; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG TARGETING; ENZYME METABOLISM; GASTROINTESTINAL TOXICITY; GENOMICS; HUMAN; INDIVIDUALIZATION; MUCOSA INFLAMMATION; NEUROTOXICITY; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT PLANNING;

ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DIHYDROURACIL DEHYDROGENASE (NADP); DNA HELICASES; DNA REPAIR; DNA-BINDING PROTEINS; ENDONUCLEASES; FLUOROURACIL; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; HUMANS; PLATINUM COMPOUNDS; PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; THYMIDYLATE SYNTHASE; TRANSCRIPTION FACTORS; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 0042303838     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(03)00082-1     Document Type: Review

References (72)

1. Cancer Facts and Figures: Edited by American Cancer Society; 2003. [URL: http://www.cancer.org/docroot/STT/stt_0.asp]
2. Walsh J.M. Terdiman J.P. Colorectal cancer screening: scientific review J. Am. Med. Assoc. 289 2003 1288-1296
3. Saltz L.B. Cox J.V. Blanke C. Rosen L.S. Fehrenbacher L. Moore M.J. Maroun J.A. Ackland S.P. Locker P.K. Pirotta N. et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group N. Engl. J. Med. 343 2000 905-914
4. Salonga D. Danenberg K.D. Johnson M. Metzger R. Groshen S. Tsao-Wei D.D. Lenz H.J. Leichman C.G. Leichman L. Diasio R.B. et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase Clin. Cancer Res. 6 2000 1322-1327
5. Nishimura G. Terada I. Kobayashi T. Ninomiya I. Kitagawa H. Fushida S. Fujimura T. Kayahara M. Shimizu K. Ohta T. et al. Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5′-deoxy-5-fluorouridine as adjuvant chemotherapy Oncol. Rep. 9 2002 479-482
6. Ladner R.D. Lynch F.J. Groshen S. Xiong Y.P. Sherrod A. Caradonna S.J. Stoehlmacher J. Lenz H.J. dUTP nucleotidohydrolase isoform expression in normal and neoplastic tissues: association with survival and response to 5-fluorouracil in colorectal cancer Cancer Res. 60 2000 3493-3503
7. Project A.C.C.M. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate J. Clin. Oncol. 10 1992 896-903
8. Leichman C.G. Lenz H.J. Leichman L. Danenberg K. Baranda J. Groshen S. Boswell W. Metzger R. Tan M. Danenberg P.V. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin J. Clin. Oncol. 15 1997 3223-3229
9. Lenz H.J. Leichman C.G. Danenberg K.D. Danenberg P.V. Groshen S. Cohen H. Laine L. Crookes P. Silberman H. Baranda J. et al. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival J. Clin. Oncol. 14 1996 176-182
10. Aschele C. Bandelloni R. Cascinu S. Catalano V. Giordani P. Barni S. Turci D. Drudi G. Lonardi S. Gallo L. et al.Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil Ann. Oncol. 13 2002 1882-1892
11. Shirota Y. Stoehlmacher J. Brabender J. Xiong Y.P. Uetake H. Danenberg K.D. Groshen S. Tsao-Wei D.D. Danenberg P.V. Lenz H.J. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy J. Clin. Oncol. 19 2001 4298-4304 A retrospective study demonstrating the value of intratumoral TS and ERCC1 gene expression as independent predictive (TS) and prognostic markers (TS and ERCC1) in patients with refractory advanced colorectal cancer undergoing 5-FU/oxaliplatin therapy.
12. Kawakami K. Omura K. Kanehira E. Watanabe Y. Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers Anticancer Res. 19 1999 3249-3252
13. Horie N. Chimoto M. Nozawa R. Takeishi K. Characterization of regulatory sequences and nuclear factors that function in cooperation with the promoter of the human thymidylate synthase gene Biochim. Biophys Acta 1216 1993 409-416
14. Horie N. Aiba H. Oguro K. Hojo H. Takeishi K. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase Cell Struct. Funct. 20 1995 191-197
15. Marsh S. Githang'a J. Indalo A. Ofori-Adjei D. McLeod H.L. Novel thymidylate synthase enhancer region alleles in African populations Hum Mutat 16 2000 528
16. Marsh S. Collie-Duguid E.S. Li T. Liu X. McLeod H.L. Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations Genomics 58 1999 310-312
17. Pullarkat ST, Ingles SA, Xiong YP, Sherrod A: Analysis of the thymidylate synthase gene polymorphism in the Latino population. In Proceeding of American Association for Cancer Research 1999:4583.
18. Kawakami K. Salonga D. Park J.M. Danenberg K.D. Uetake H. Brabender J. Omura K. Watanabe G. Danenberg P.V. Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression Clin. Cancer Res. 7 2001 4096-4101
19. Pullarkat S.T. Stoehlmacher J. Ghaderi V. Xiong Y.P. Ingles S.A. Sherrod A. Warren R. Tsao-Wei D. Groshen S. Lenz H.J. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy Pharmacogenomics J. 1 2001 65-70
20. Etienne M.C. Chazal M. Laurent-Puig P. Magne N. Rosty C. Formento J.L. Francoual M. Formento P. Renee N. Chamorey E. et al. Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses J. Clin. Oncol. 20 2002 2832-2843
21. Marsh S. McKay J.A. Cassidy J. McLeod H.L. Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer Int. J. Oncol. 19 2001 383-386
22. Iacopetta B. Grieu F. Joseph D. Elsaleh H. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil Br. J. Cancer 85 2001 827-830
23. Paulo M. Hoff R.A. Batist G. Cox J. Kocha W. Kuperminc M. Maroun J. Walde D. Weaver C. Harrison E. et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study J. Clin. Oncol. 19 2001 2282-2292
24. Park D.J. Stoehlmacher J. Zhang W. Tsao-Wei D. Groshen S. Lenz H.J. Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer Int. J. Colorectal Dis. 17 2002 46-49
25. Ulrich C.M. Bigler J.Velicer C.M. Greene E.A. Farin F.M. Potter J.D. Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene Cancer Epidemiol Biomarkers Prev 9 2000 1381-1385
26. Mandola M.V. Stoehlmacher J. Muller-Weeks S. Cesarone G. Yu M. Lenz H.-J. Ladner R. A novel single nucleotide polymorphism within the 5′ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity Cancer Res. 63 2003 2898-2904
27. Heggie G.D. Sommadossi J.P. Cross D.S. Huster W.J. Diasio R.B. Clinical pharmacokinetics of 5-fluorouracil and its metabolism in plasma Cancer Res. 47 1987-2203
28. Etienne M.C. Lagrange J.L. Dassonville O. Fleming R. Thyss A. Renee N. Schneider M. Demard F. Milano G. Population study of dihydropyrimidine dehydrogenase in cancer patients J. Clin. Oncol. 12 1994 2248-2253
29. Lu Z. Zhang R. Diasio R.B. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy Cancer Res. 53 1993 5433-5438
30. Johnson M.R. Hageboutros A. Wang K. High L. Smith J.B. Diasio R.B. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil Clin Cancer Res. 5 1999 2006-2011
31. Milano G. Etienne M.C. Pierrefite V. Barberi-Heyob M. Deporte-Fety R. Renee N. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity Br. J. Cancer 79 1999 627-630
32. Milano G. Etienne M.C. Potential importance of dihydropyrimidine dehydrogenase (DPD) in cancer chemotherapy Pharmacogenetics 4 1994 301-306
33. Wei X.M. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity J. Clin. Invest 98 1996 610-615
34. Van Kuilenburg A.B. Vreken P. Beex L.V. Meinsma R. Van Lenthe H. De Abreu R.A. Van Gennip A.H. Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity Eur. J. Cancer 33 1997 2258-2264
35. Van Kuilenburg A.B. Muller E.W. Haasjes J. Meinsma R. Zoetekouw L. Waterham H.R. Baas F. Richel D.J. van Gennip A.H. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency Clin Cancer Res. 7 2001 1149-1153
36. Raida M. Schwabe W. Hausler P. Van Kuilenburg A.B. Van Gennip A.H. Behnke D. Hoffken K. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls Clin. Cancer Res. 7 2001 2832-2839
37. Innocenti F. Ratain M.J. Correspondence re: Raida, M. et al., prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls Clinical Cancer Research 8 2002 1314
38. Behnke D.M.R. Kliche K.-O. Pichlmeier U. Reply Clin Cancer Res. 8 2002 1315-1316
39. Humerickhouse R. Lohrbach K. Li L. Bosron W.F. Dolan M.E. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2 Cancer Res. 60 2000 1189-1192
40. Iyer L. Hall D. Das S. Mortell M.A. Ramirez J. Kim S. Di Rienzo A. Ratain M.J. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism Clin. Pharmacol. Ther. 65 1999 576-582
41. Iyer L. Das S. Janisch L. Wen M. Ramirez J. Karrison T. Fleming G.F. Vokes E.E. Schilsky R.L. Ratain M.J. UGT1A1* 28 polymorphism as a determinant of irinotecan disposition and toxicity Pharmacogenomics J. 2 2002 43-47
42. Johnson N.P. Hoeschele J.D. Rahn R.O. Kinetic analysis of the in vitro binding of radioactive cis- and trans-dichlorodiammineplatinum(II) to DNA Chem. Biol. Interact 30 1980 151-169
43. Reardon JT, Sancar A: Molecular Mechanism of Nucleotide Excision Repair in Mammalian Cells. Edited by Dizdaroglu M, Karakaya A. New York: Plenum Publishing Corp.; 1998:377-393.
44. Wilson M.D. Ruttan C.C. Koop B.F. Glickman B.W. ERCC1: a comparative genomic perspective Environ. Mol. Mutagen 38 2001 209-215
45. Metzger R. Leichman C.G. Danenberg K.D. Danenberg P.V. Lenz H.J. Hayashi K. Groshen S. Salonga D. Cohen H. Laine L. et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy J. Clin. Oncol. 16 1998 309-316
46. Dabholkar M. Bostick-Bruton F. Weber C. Bohr V.A. Egwuagu C. Reed E. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients J. Natl. Cancer Inst. 84 1992 1512-1517
47. Dabholkar M. Vionnet J. Bostick-Bruton F. Yu J.J. Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy J. Clin. Invest 94 1994 703-708
48. Arnould S. Hennebelle I. Canal P. Bugat R. Guichard S. Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines Eur. J. Cancer 39 2003 112-119
49. Park D. Zhang W. Stoehlmacher J. Tsao-Wei D. Groshen S. Gil J. Yun J. Sones E. Mallik N. Lenz H.-J. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy Clinical Advances in Hematology and Oncology 1 2003 120-124
50. Park D, Stoehlmacher J, Zhang W, Tsao-Wei D, Groshen S, Zahedy S, Gil J, Mallik N, Lenz H-J: ERCC1 polymorphism is associated with differential ERCC1 mRNA levels [abstract]. In American Association for Cancer Research. San Francisco, CA; 2002:1591.
51. Sung P. Bailly V. Weber C. Thompson L.H. Prakash L. Prakash S. Human xeroderma pigmentosum group D gene encodes a DNA helicase Nature 365 1993 852-855
52. Coin F. Marinoni J.C. Rodolfo C. Fribourg S. Pedrini A.M. Egly J.M. Mutations in the XPD helicase gene result in XP and TTD phenotypes, preventing interaction between XPD and the p44 subunit of TFIIH Nat Genet. 20 1998 184-188
53. Xu Z. Chen Z.P. Malapetsa A. Alaoui-Jamali M. Bergeron J. Monks A. Myers T.G. Mohr G. Sausville E.A. Scudiero D.A. et al. DNA repair protein levels vis-a-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program Anticancer Drugs 13 2002 511-519
54. Lunn R.M. Helzlsouer K.J. Parshad R. Umbach D.M. Harris E.L. Sanford K.K. Bell D.A. XPD polymorphisms: effects on DNA repair proficiency Carcinogenesis 21 2000 551-555
55. Park D.J. Stoehlmacher J. Zhang W. Tsao-Wei D.D. Groshen S. Lenz H.J. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer Cancer Res. 61 2001 8654-8658
56. Lenz HJ, Park D, Zhang W: A multivariate analysis of genetic markers for clinical response to 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer [abstract]. In Proceedings American Society of Clinical Oncologists. Orlando, Florida: 2002.
57. Siciliano M.J. Carrano A.V. Thompson L.H. Assignment of a human DNA-repair gene associated with sister-chromatid exchange to chromosome 19 Mutat Res. 174 1986 303-308
58. Thompson L.H. Brookman K.W. Jones N.J. Allen S.A. Carrano A.V. Molecular cloning of the human XRCC1 gene, which corrects defective DNA strand break repair and sister chromatid exchange Mol. Cell. Biol. 10 1990 6160-6171
59. Zdzienicka M.Z. van der Schans G.P. Natarajan A.T. Thompson L.H. Neuteboom I. Simons J.W. A Chinese hamster ovary cell mutant (EM-C11) with sensitivity to simple alkylating agents and a very high level of sister chromatid exchanges Mutagenesis 7 1992 265-269
60. Stoehlmacher J. Ghaderi V. Iobal S. Groshen S. Tsao-Wei D. Park D. Lenz H.J. A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer Anticancer Res. 21 2001 3075-3079
61. Moscow J.A. Fairchild C.R. Madden M.J. Ransom D.T. Wieand H.S. O'Brien E.E. Poplack D.G. Cossman J. Myers C.E. Cowan K.H. Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors Cancer Res. 49 1989 1422-1428
62. Goto S. Iida T. Cho S. Oka M. Kohno S. Kondo T. Overexpression of glutathione S-transferase pi enhances the adduct formation of cisplatin with glutathione in human cancer cells Free Radic Res. 31 1999 549-558
63. Watson M.A. Stewart R.K. Smith G.B. Massey T.E. Bell D.A. Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution Carcinogenesis 19 1998 275-280
64. Stoehlmacher J. Park D.J. Zhang W. Groshen S. Tsao-Wei D.D. Yu M.C. Lenz H.J. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer J. Natl. Cancer Inst. 94 2002 936-942.
65. Zwick E. Hackel P.O. Prenzel N. Ullrich A. The EGF receptor as central transducer of heterologous signaling systems Trends Pharmacol. Sci. 20 1999 408-412
66. McKay J.A. Murray L.J. Curran S. Ross V.G. Clark C. Murray G.I. Cassidy J. McLeod H.L. Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases Eur. J. Cancer 38 2002 2258-2264
67. Dickstein B.M. Wosikowski K. Bates S.E. Increased resistance to cytotoxic agents in ZR75B human breast cancer cells transfected with epidermal growth factor receptor Mol. Cell. Endocrinol. 110 1995 205-211
68. Ogawa J. Iwazaki M.Inoue H.Koide S.Shohtsu A.Immunohistochemical study of glutathione-related enzymes and proliferative antigens in lung cancer. Relation to cisplatin sensitivity Cancer 71 1993 2204-2209
69. Mroczkowski B. Mosig G. Cohen S. STP-stimulated interaction between epidermal growth factor receptor and supercoiled DNA Nature 309 1984 270-273
70. Eldredge E.R. Korf G.M. Christensen T.A. Connolly D.C. Getz M.J. Maihle N.J. Activation of c-fos gene expression by a kinase-deficient epidermal growth factor receptor Mol. Cell. Biol. 14 1994 7527-7534
71. Gebhardt F. Zanker K.S. Brandt B. Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1 J. Biol. Chem. 274 1999 13176-13180
72. Wu Zhang JS, Park DJ, Groshen S, Tsao-Wei D, Zahedy S, Lu B, Gil J, Mallik N, Lenz HJ: A polymorphic dinucleotide repeat in intron 1 of EGFR (epithelial growth factor receptor) gene is associated with clinical response to platinum based chemotherapy in patients with advanced colorectal disease [abstract]. In American Society of Clinical Oncology. Orlando, FL; 2002:533.